Skip to main content
Top
Published in: Endocrine Pathology 3/2008

01-09-2008

Molecular Detection of PPARγ Rearrangements and Thyroid Carcinoma in Preoperative Fine-Needle Aspiration Biopsies

Authors: Christopher A. French, Jonathan A. Fletcher, Edmund S. Cibas, Christopher Caulfield, Paulette Allard, Todd G. Kroll

Published in: Endocrine Pathology | Issue 3/2008

Login to get access

Abstract

The pathologic diagnosis of thyroid follicular tumors is difficult, particularly in preoperative fine-needle aspiration biopsies. To investigate whether the molecular diagnosis of PPARγ rearrangements can detect thyroid carcinomas in fine-needle aspiration biopsies, we performed interphase fluorescence in situ hybridization on 24 thyroid fine-needle aspiration and 17 follow-up thyroidectomy specimens. Two of the 24 fine-needle aspiration biopsies contained PPARγ rearrangements, and both were diagnosed suggestive of a thyroid follicular neoplasm by cytology. The two corresponding thyroidectomies each contained PPARγ rearrangements in all tumor cells and, both were diagnosed follicular-patterned thyroid carcinomas—one a follicular carcinoma and the other a follicular variant of papillary carcinoma, the latter by majority of expert endocrine pathologists. Our experiments demonstrate that PPARγ rearrangements can detect a subset of follicular-patterned thyroid carcinomas in preoperative thyroid fine-needle aspiration biopsies. The ultimate utility of mutations such as PPARγ rearrangements in diagnosis of thyroid carcinoma must be proven by direct correlation of mutation status with thyroid tumor biology and not just with thyroid tumor morphology, a subjective and imprecise marker of clinical behavior. The application of specific mutations to preoperative diagnosis of thyroid carcinoma is predicted to improve the accuracy and reduce the costs of treating patients with thyroid tumors.
Literature
1.
go back to reference Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 126:226–31, 1997.PubMed Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 126:226–31, 1997.PubMed
3.
go back to reference Bruneton JN, Balu-Maestro C, Marcy PY, Melia P, Mourou MY. Very high frequency (13 mhz) ultrasonographic examination of the normal neck: Detection of normal lymph nodes and thyroid nodules. J Ultrasound Med 13:87–90, 1994.PubMed Bruneton JN, Balu-Maestro C, Marcy PY, Melia P, Mourou MY. Very high frequency (13 mhz) ultrasonographic examination of the normal neck: Detection of normal lymph nodes and thyroid nodules. J Ultrasound Med 13:87–90, 1994.PubMed
4.
go back to reference DeLellis R, Lloyd R, Heitz P, Eng C. (eds.) Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press pp. 49–133, 2004. DeLellis R, Lloyd R, Heitz P, Eng C. (eds.) Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press pp. 49–133, 2004.
7.
go back to reference Saxen E, Franssila K, Bjarnason O, Normann T, Ringertz N. Observer variation in histologic classification of thyroid cancer. Acta Pathol Microbiol Scand [A] 86A:483–6, 1978. Saxen E, Franssila K, Bjarnason O, Normann T, Ringertz N. Observer variation in histologic classification of thyroid cancer. Acta Pathol Microbiol Scand [A] 86A:483–6, 1978.
10.
go back to reference Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, Chan JK, DeLellis RA, Harach HR, Kakudo K, LiVolsi VA, Rosai J, Sebo TJ, Sobrinho-Simoes M, Wenig BM, Lae ME. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28:1336–40, 2004. doi:10.1097/01.pas.0000135519.34847.f6.PubMedCrossRef Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, Chan JK, DeLellis RA, Harach HR, Kakudo K, LiVolsi VA, Rosai J, Sebo TJ, Sobrinho-Simoes M, Wenig BM, Lae ME. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28:1336–40, 2004. doi:10.​1097/​01.​pas.​0000135519.​34847.​f6.PubMedCrossRef
13.
go back to reference Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med 118:282–9, 1993.PubMed Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med 118:282–9, 1993.PubMed
15.
go back to reference Grant CS, Hay ID, Gough IR, McCarthy PM, Goellner JR. Long-term follow-up of patients with benign thyroid fine-needle aspiration cytologic diagnoses. Surgery 106:980–5, 1989, discussion 85–6.PubMed Grant CS, Hay ID, Gough IR, McCarthy PM, Goellner JR. Long-term follow-up of patients with benign thyroid fine-needle aspiration cytologic diagnoses. Surgery 106:980–5, 1989, discussion 85–6.PubMed
16.
go back to reference Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Melillo R, Pierotti MA, Bongarzone I, Della Porta G, Berger N, et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 89:1517–22, 1992. doi:10.1172/JCI115743.PubMedCrossRef Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Melillo R, Pierotti MA, Bongarzone I, Della Porta G, Berger N, et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 89:1517–22, 1992. doi:10.​1172/​JCI115743.PubMedCrossRef
18.
go back to reference Fusco A, Grieco M, Santoro M, Berlingieri MT, Pilotti S, Pierotti MA, Della Porta G, Vecchio G. A new oncogene in human thyroid papillary carcinomas and their lymph–nodal metastases. Nature 328:170–2, 1987. doi:10.1038/328170a0.PubMedCrossRef Fusco A, Grieco M, Santoro M, Berlingieri MT, Pilotti S, Pierotti MA, Della Porta G, Vecchio G. A new oncogene in human thyroid papillary carcinomas and their lymph–nodal metastases. Nature 328:170–2, 1987. doi:10.​1038/​328170a0.PubMedCrossRef
19.
go back to reference Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G. Ptc is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557–63, 1990. doi:10.1016/0092-8674(90)90659-3.PubMedCrossRef Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G. Ptc is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557–63, 1990. doi:10.​1016/​0092-8674(90)90659-3.PubMedCrossRef
20.
go back to reference Rabes HM, Demidchik EP, Sidorow JD, Lengfelder E, Beimfohr C, Hoelzel D, Klugbauer S. Pattern of radiation-induced ret and ntrk1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res 6:1093–103, 2000.PubMed Rabes HM, Demidchik EP, Sidorow JD, Lengfelder E, Beimfohr C, Hoelzel D, Klugbauer S. Pattern of radiation-induced ret and ntrk1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res 6:1093–103, 2000.PubMed
21.
go back to reference Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57:1690–4, 1997.PubMed Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57:1690–4, 1997.PubMed
22.
go back to reference Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138:409–16, 2003, discussion 16.PubMedCrossRef Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138:409–16, 2003, discussion 16.PubMedCrossRef
23.
go back to reference Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, et al. Germ-line mutations of the ret proto-oncogene in multiple endocrine neoplasia type 2a. Nature 363:458–60, 1993. doi:10.1038/363458a0.PubMedCrossRef Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, et al. Germ-line mutations of the ret proto-oncogene in multiple endocrine neoplasia type 2a. Nature 363:458–60, 1993. doi:10.​1038/​363458a0.PubMedCrossRef
24.
go back to reference Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr. Mutations in the ret proto-oncogene are associated with men 2a and fmtc. Hum Mol Genet 2:851–6, 1993. doi:10.1093/hmg/2.7.851.PubMedCrossRef Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr. Mutations in the ret proto-oncogene are associated with men 2a and fmtc. Hum Mol Genet 2:851–6, 1993. doi:10.​1093/​hmg/​2.​7.​851.PubMedCrossRef
25.
go back to reference Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D. Braf mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625–7, 2003.PubMedCrossRef Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D. Braf mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625–7, 2003.PubMedCrossRef
26.
go back to reference Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of braf mutations in thyroid cancer: genetic evidence for constitutive activation of the ret/ptc-ras-braf signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–7, 2003.PubMed Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of braf mutations in thyroid cancer: genetic evidence for constitutive activation of the ret/ptc-ras-braf signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–7, 2003.PubMed
27.
go back to reference Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE. Braf mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–404, 2003. doi:10.1210/jc.2003-030838.PubMedCrossRef Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE. Braf mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–404, 2003. doi:10.​1210/​jc.​2003-030838.PubMedCrossRef
28.
go back to reference Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW. Braf mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373–9, 2005. doi:10.1210/jc.2005-0987.PubMedCrossRef Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW. Braf mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373–9, 2005. doi:10.​1210/​jc.​2005-0987.PubMedCrossRef
29.
go back to reference Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S. Clinical implication of hot spot braf mutation, v599e, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393–7, 2003. doi:10.1210/jc.2003-030305.PubMedCrossRef Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S. Clinical implication of hot spot braf mutation, v599e, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393–7, 2003. doi:10.​1210/​jc.​2003-030305.PubMedCrossRef
30.
go back to reference Wright PA, Lemoine NR, Mayall ES, Wyllie FS, Hughes D, Williams ED, Wynford-Thomas D. Papillary and follicular thyroid carcinomas show a different pattern of ras oncogene mutation. Br J Cancer 60:576–7, 1989.PubMed Wright PA, Lemoine NR, Mayall ES, Wyllie FS, Hughes D, Williams ED, Wynford-Thomas D. Papillary and follicular thyroid carcinomas show a different pattern of ras oncogene mutation. Br J Cancer 60:576–7, 1989.PubMed
31.
go back to reference Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4:1474–9, 1990.PubMed Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4:1474–9, 1990.PubMed
32.
go back to reference Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B, Wynford-Thomas D. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4:159–64, 1989.PubMed Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B, Wynford-Thomas D. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4:159–64, 1989.PubMed
35.
go back to reference Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW 2nd, Tallini G, Kroll TG, Nikiforov YE. Ras point mutations and pax8-ppar gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88:2318–26, 2003. doi:10.1210/jc.2002-021907.PubMedCrossRef Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW 2nd, Tallini G, Kroll TG, Nikiforov YE. Ras point mutations and pax8-ppar gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88:2318–26, 2003. doi:10.​1210/​jc.​2002-021907.PubMedCrossRef
36.
go back to reference Basolo F, Pisaturo F, Pollina LE, Fontanini G, Elisei R, Molinaro E, Iacconi P, Miccoli P, Pacini F. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 10:19–23, 2000.PubMedCrossRef Basolo F, Pisaturo F, Pollina LE, Fontanini G, Elisei R, Molinaro E, Iacconi P, Miccoli P, Pacini F. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 10:19–23, 2000.PubMedCrossRef
37.
go back to reference French CA, Alexander EK, Cibas ES, Nose V, Laguette J, Faquin W, Garber J, Moore F Jr., Fletcher JA, Larsen PR, Kroll TG. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 162:1053–60, 2003.PubMed French CA, Alexander EK, Cibas ES, Nose V, Laguette J, Faquin W, Garber J, Moore F Jr., Fletcher JA, Larsen PR, Kroll TG. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 162:1053–60, 2003.PubMed
38.
go back to reference Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger P, Doherty G, Thompson NW, Hanash S, Koenig RJ, Nikiforov YE. Molecular classification of papillary thyroid carcinoma: Distinct braf, ras, and ret/ptc mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24:6646–56, 2005. doi:10.1038/sj.onc.1208822.PubMedCrossRef Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger P, Doherty G, Thompson NW, Hanash S, Koenig RJ, Nikiforov YE. Molecular classification of papillary thyroid carcinoma: Distinct braf, ras, and ret/ptc mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24:6646–56, 2005. doi:10.​1038/​sj.​onc.​1208822.PubMedCrossRef
39.
go back to reference Sapio MR, Posca D, Raggioli A, Guerra A, Marotta V, Deandrea M, Motta M, Limone PP, Troncone G, Caleo A, Rossi G, Fenzi G, Vitale M. Detection of ret/ptc, trk and braf mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) 66:678–83, 2007. doi:10.1111/j.1365-2265.2007.02800.x.CrossRef Sapio MR, Posca D, Raggioli A, Guerra A, Marotta V, Deandrea M, Motta M, Limone PP, Troncone G, Caleo A, Rossi G, Fenzi G, Vitale M. Detection of ret/ptc, trk and braf mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) 66:678–83, 2007. doi:10.​1111/​j.​1365-2265.​2007.​02800.​x.CrossRef
40.
go back to reference Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, Sidransky D, Westra WH. Mutational analysis of braf in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 10:2761–5, 2004. doi:10.1158/1078-0432.CCR-03-0273.PubMedCrossRef Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, Sidransky D, Westra WH. Mutational analysis of braf in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 10:2761–5, 2004. doi:10.​1158/​1078-0432.​CCR-03-0273.PubMedCrossRef
41.
go back to reference Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park do J, Lee HS, Cho BY, Lee ES, Kim SW. Detection of brafv600e mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in braf600e mutation-prevalent area. Clin Endocrinol (Oxf) 65:660–6, 2006. doi:10.1111/j.1365-2265.2006.02646.x.CrossRef Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park do J, Lee HS, Cho BY, Lee ES, Kim SW. Detection of brafv600e mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in braf600e mutation-prevalent area. Clin Endocrinol (Oxf) 65:660–6, 2006. doi:10.​1111/​j.​1365-2265.​2006.​02646.​x.CrossRef
42.
go back to reference Pizzolanti G, Russo L, Richiusa P, Bronte V, Nuara RB, Rodolico V, Amato MC, Smeraldi L, Sisto PS, Nucera M, Bommarito A, Citarrella R, Lo Coco R, Cabibi D, Lo Coco A, Frasca F, Gulotta G, Latteri MA, Modica G, Galluzzo A, Giordano C. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through braf v600e mutation and ret/ptc rearrangement. Thyroid 17:1109–15, 2007. doi:10.1089/thy.2007.0008.PubMedCrossRef Pizzolanti G, Russo L, Richiusa P, Bronte V, Nuara RB, Rodolico V, Amato MC, Smeraldi L, Sisto PS, Nucera M, Bommarito A, Citarrella R, Lo Coco R, Cabibi D, Lo Coco A, Frasca F, Gulotta G, Latteri MA, Modica G, Galluzzo A, Giordano C. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through braf v600e mutation and ret/ptc rearrangement. Thyroid 17:1109–15, 2007. doi:10.​1089/​thy.​2007.​0008.PubMedCrossRef
43.
45.
go back to reference Xing M, Tufano RP, Tufaro AP, Basaria S, Ewertz M, Rosenbaum E, Byrne PJ, Wang J, Sidransky D, Ladenson PW. Detection of braf mutation on fine needle aspiration biopsy specimens: A new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 89:2867–72, 2004. doi:10.1210/jc.2003-032050.PubMedCrossRef Xing M, Tufano RP, Tufaro AP, Basaria S, Ewertz M, Rosenbaum E, Byrne PJ, Wang J, Sidransky D, Ladenson PW. Detection of braf mutation on fine needle aspiration biopsy specimens: A new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 89:2867–72, 2004. doi:10.​1210/​jc.​2003-032050.PubMedCrossRef
46.
go back to reference Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F, Santoro M. Analysis of braf point mutation and ret/ptc rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 89:5175–80, 2004. doi:10.1210/jc.2003-032221.PubMedCrossRef Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F, Santoro M. Analysis of braf point mutation and ret/ptc rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 89:5175–80, 2004. doi:10.​1210/​jc.​2003-032221.PubMedCrossRef
48.
go back to reference Giordano TJ, Au AY, Kuick R, Thomas DG, Rhodes DR, Wilhelm KG Jr., Vinco M, Misek DE, Sanders D, Zhu Z, Ciampi R, Hanash S, Chinnaiyan A, Clifton-Bligh RJ, Robinson BG, Nikiforov YE, Koenig RJ. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the pax8-pparg translocation. Clin Cancer Res 12:1983–93, 2006. doi:10.1158/1078-0432.CCR-05-2039.PubMedCrossRef Giordano TJ, Au AY, Kuick R, Thomas DG, Rhodes DR, Wilhelm KG Jr., Vinco M, Misek DE, Sanders D, Zhu Z, Ciampi R, Hanash S, Chinnaiyan A, Clifton-Bligh RJ, Robinson BG, Nikiforov YE, Koenig RJ. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the pax8-pparg translocation. Clin Cancer Res 12:1983–93, 2006. doi:10.​1158/​1078-0432.​CCR-05-2039.PubMedCrossRef
49.
go back to reference Lui WO, Foukakis T, Liden J, Thoppe SR, Dwight T, Hoog A, Zedenius J, Wallin G, Reimers M, Larsson C. Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a pax8-ppar(gamma) fusion oncogene. Oncogene 24:1467–76, 2005. doi:10.1038/sj.onc.1208135.PubMedCrossRef Lui WO, Foukakis T, Liden J, Thoppe SR, Dwight T, Hoog A, Zedenius J, Wallin G, Reimers M, Larsson C. Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a pax8-ppar(gamma) fusion oncogene. Oncogene 24:1467–76, 2005. doi:10.​1038/​sj.​onc.​1208135.PubMedCrossRef
50.
go back to reference Lui W, Zeng L, Rehrmann V, Deshpande S, Tretiakova M, Kaplan E, Leibiger I, Leibiger B, Enberg U, Hoog A, Larsson C, Kroll T. CREB3L2-PPARγ fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. Cancer Res (in press), 2008. Lui W, Zeng L, Rehrmann V, Deshpande S, Tretiakova M, Kaplan E, Leibiger I, Leibiger B, Enberg U, Hoog A, Larsson C, Kroll T. CREB3L2-PPARγ fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. Cancer Res (in press), 2008.
51.
go back to reference Powell J, Wang X, Allard B, Sahin M, Wang X-L, Hay I, Hiddinga H, Desphande S, Kroll T, Grebe S, Eberhardt N, McIver B. The pax8/pparg fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type pparg inhibition. Oncogene 23:3634–41, 2004. doi:10.1038/sj.onc.1207399.CrossRef Powell J, Wang X, Allard B, Sahin M, Wang X-L, Hay I, Hiddinga H, Desphande S, Kroll T, Grebe S, Eberhardt N, McIver B. The pax8/pparg fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type pparg inhibition. Oncogene 23:3634–41, 2004. doi:10.​1038/​sj.​onc.​1207399.CrossRef
53.
go back to reference Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, Leite V. Expression of pax8-ppargamma1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87:3947–52, 2002. doi:10.1210/jc.87.8.3947.PubMedCrossRef Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, Leite V. Expression of pax8-ppargamma1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87:3947–52, 2002. doi:10.​1210/​jc.​87.​8.​3947.PubMedCrossRef
54.
go back to reference Lacroix L, Mian C, Barrier T, Talbot M, Caillou B, Schlumberger M, Bidart JM. Pax8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. Eur J Endocrinol 151:367–74, 2004. doi:10.1530/eje.0.1510367.PubMedCrossRef Lacroix L, Mian C, Barrier T, Talbot M, Caillou B, Schlumberger M, Bidart JM. Pax8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. Eur J Endocrinol 151:367–74, 2004. doi:10.​1530/​eje.​0.​1510367.PubMedCrossRef
55.
go back to reference Dwight T, Thoppe SR, Foukakis T, Lui WO, Wallin G, Hoog A, Frisk T, Larsson C, Zedenius J. Involvement of the pax8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 88:4440–5, 2003. doi:10.1210/jc.2002–021690.PubMedCrossRef Dwight T, Thoppe SR, Foukakis T, Lui WO, Wallin G, Hoog A, Frisk T, Larsson C, Zedenius J. Involvement of the pax8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 88:4440–5, 2003. doi:10.​1210/​jc.​2002–021690.PubMedCrossRef
56.
go back to reference Cheung L, Messina M, Gill A, Clarkson A, Learoyd D, Delbridge L, Wentworth J, Philips J, Clifton-Bligh R, Robinson BG. Detection of the pax8-ppar gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 88:354–7, 2003. doi:10.1210/jc.2002–021020.PubMedCrossRef Cheung L, Messina M, Gill A, Clarkson A, Learoyd D, Delbridge L, Wentworth J, Philips J, Clifton-Bligh R, Robinson BG. Detection of the pax8-ppar gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 88:354–7, 2003. doi:10.​1210/​jc.​2002–021020.PubMedCrossRef
58.
go back to reference Lacroix L, Lazar V, Michiels S, Ripoche H, Dessen P, Talbot M, Caillou B, Levillain JP, Schlumberger M, Bidart JM. Follicular thyroid tumors with the pax8-ppargamma1 rearrangement display characteristic genetic alterations. Am J Pathol 167:223–31, 2005.PubMed Lacroix L, Lazar V, Michiels S, Ripoche H, Dessen P, Talbot M, Caillou B, Levillain JP, Schlumberger M, Bidart JM. Follicular thyroid tumors with the pax8-ppargamma1 rearrangement display characteristic genetic alterations. Am J Pathol 167:223–31, 2005.PubMed
60.
go back to reference Chiappetta G, Toti P, Cetta F, Giuliano A, Pentimalli F, Amendola I, Lazzi S, Monaco M, Mazzuchelli L, Tosi P, Santoro M, Fusco A. The ret/ptc oncogene is frequently activated in oncocytic thyroid tumors (hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J Clin Endocrinol Metab 87:364–9, 2002. doi:10.1210/jc.87.1.364.PubMedCrossRef Chiappetta G, Toti P, Cetta F, Giuliano A, Pentimalli F, Amendola I, Lazzi S, Monaco M, Mazzuchelli L, Tosi P, Santoro M, Fusco A. The ret/ptc oncogene is frequently activated in oncocytic thyroid tumors (hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J Clin Endocrinol Metab 87:364–9, 2002. doi:10.​1210/​jc.​87.​1.​364.PubMedCrossRef
61.
go back to reference Belchetz G, Cheung CC, Freeman J, Rosen IB, Witterick IJ, Asa SL. Hurthle cell tumors: Using molecular techniques to define a novel classification system. Arch Otolaryngol Head Neck Surg 128:237–40, 2002.PubMed Belchetz G, Cheung CC, Freeman J, Rosen IB, Witterick IJ, Asa SL. Hurthle cell tumors: Using molecular techniques to define a novel classification system. Arch Otolaryngol Head Neck Surg 128:237–40, 2002.PubMed
62.
go back to reference van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009, 2002. doi:10.1056/NEJMoa021967.PubMedCrossRef van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009, 2002. doi:10.​1056/​NEJMoa021967.PubMedCrossRef
63.
go back to reference Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 406:747–52, 2000. doi:10.1038/35021093.PubMedCrossRef Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 406:747–52, 2000. doi:10.​1038/​35021093.PubMedCrossRef
64.
go back to reference Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ. Mll translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30:41–7, 2002. doi:10.1038/ng765.PubMedCrossRef Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ. Mll translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30:41–7, 2002. doi:10.​1038/​ng765.PubMedCrossRef
65.
go back to reference Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui CH, Evans WE, Naeve C, Wong L, Downing JR. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133–43, 2002. doi:10.1016/S1535–6108(02)00032–6.PubMedCrossRef Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui CH, Evans WE, Naeve C, Wong L, Downing JR. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133–43, 2002. doi:10.​1016/​S1535–6108(02)00032–6.PubMedCrossRef
Metadata
Title
Molecular Detection of PPARγ Rearrangements and Thyroid Carcinoma in Preoperative Fine-Needle Aspiration Biopsies
Authors
Christopher A. French
Jonathan A. Fletcher
Edmund S. Cibas
Christopher Caulfield
Paulette Allard
Todd G. Kroll
Publication date
01-09-2008
Publisher
Humana Press Inc
Published in
Endocrine Pathology / Issue 3/2008
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-008-9036-0

Other articles of this Issue 3/2008

Endocrine Pathology 3/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.